Next Article in Journal / Special Issue
Antiproliferative Activity of (-)-Rabdosiin Isolated from Ocimum sanctum L.
Previous Article in Journal / Special Issue
Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle

Development and Validation of an HPLC-PDA Method for Biologically Active Quinonemethide Triterpenoids Isolated from Maytenus chiapensis

1
Instituto Universitario de Bio-Orgánica Antonio González, Departamento de Química Orgánica, Universidad de La Laguna, Avenida Astrofísico Francisco Sánchez 2, 38206 La Laguna, Tenerife, Spain
2
Dipartimento di Farmacia, Università degli Studi “G. d’Annunzio” Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
3
Laboratorio de Investigación en Productos Naturales, Facultad de Química y Farmacia, Universidad de El Salvador, Final Av. de Mártires y Héroes del 30 de Julio, San Salvador 1101, El Salvador
4
Museo de Historia Natural de El Salvador, Ministerio de Cultura, San Salvador 1101, El Salvador
*
Author to whom correspondence should be addressed.
Medicines 2019, 6(1), 36; https://doi.org/10.3390/medicines6010036
Received: 24 January 2019 / Revised: 22 February 2019 / Accepted: 4 March 2019 / Published: 7 March 2019
(This article belongs to the Special Issue Biological Potential and Medical Use of Secondary Metabolites)
  |  
PDF [473 KB, uploaded 7 March 2019]
  |  

Abstract

Background: Quinonemethide triterpenoids, known as celastroloids, constitute a relatively small group of biologically active compounds restricted to the Celastraceae family and, therefore, they are chemotaxonomic markers for this family. Among this particular type of metabolite, pristimerin and tingenone are considered traditional medicines in Latin America. The aim of this study was the isolation of the most abundant celastroloids from the root bark of Maytenus chiapensis, and thereafter, to develop an analytical method to identify pristimerin and tingenone in the Celastraceae species. Methods: Pristimerin and tingenone were isolated from the n-hexane-Et2O extract of the root bark of M. chiapensis through chromatographic techniques, and were used as internal standards. Application of a validated RP HPLC-PDA method was developed for the simultaneous quantification of these two metabolites in three different extracts, n-hexane-Et2O, methanol, and water, to determine the best extractor solvent. Results: Concentration values showed great variation between the solvents used for extraction, with the n-hexane–Et2O extract being the richest in pristimerin and tingenone. Conclusions: M. chiapensis is a source of two biologically active quinonemethide triterpenoids. An analytical method was developed for the qualification and quantification of these two celastroloids in the root bark extracts of M. chiapensis. The validated method reported herein could be extended and be useful in analyzing Celastraceae species and real commercial samples. View Full-Text
Keywords: Maytenus chiapensis; Celastraceae; quinonemethide triterpenoids; pristimerin; tingenone; HPLC-PDA Maytenus chiapensis; Celastraceae; quinonemethide triterpenoids; pristimerin; tingenone; HPLC-PDA
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Taddeo, V.A.; Castillo, U.G.; Martínez, M.L.; Menjivar, J.; Jiménez, I.A.; Núñez, M.J.; Bazzocchi, I.L. Development and Validation of an HPLC-PDA Method for Biologically Active Quinonemethide Triterpenoids Isolated from Maytenus chiapensis. Medicines 2019, 6, 36.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top